[1]王珏,张彩霞*.宫瘤消胶囊联合诺雷德治疗子宫内膜异位症的 临床疗效研究[J].中国计划生育和妇产科,2019,(6):75-78.
 WANG Jue,ZHANG Cai-xia*.Clinical efficacy of Gongliuxiao Capsule combined with Zoladex in the treatment of endometriosis[J].Chinese Journal of Family Planning & Gynecotokology,2019,(6):75-78.
点击复制

宫瘤消胶囊联合诺雷德治疗子宫内膜异位症的 临床疗效研究
分享到:

《中国计划生育和妇产科》[ISSN:1674-4020/CN:51-1708/R]

卷:
期数:
2019年6期
页码:
75-78
栏目:
论著与临床
出版日期:
2019-06-25

文章信息/Info

Title:
Clinical efficacy of Gongliuxiao Capsule combined with Zoladex in the treatment of endometriosis
作者:
王珏张彩霞*
神木市医院妇产科
Author(s):
WANG Jue ZHANG Cai-xia*
Department of Obstetrics and Gynecology, Shenmu City Hospital,Yulin Shaanxi 719300,P.R.China
关键词:
子宫内膜异位症宫瘤消胶囊雷诺德临床疗效
Keywords:
endometriosis Gongliuxiao Capsule Zoladex clinical efficacy
分类号:
R 71171
摘要:
目的探讨宫瘤消胶囊联合诺雷德治疗子宫内膜异位症的临床疗效。方法回顾性分析2017年3月至2018年2月陕西神木市医院收治的84例子宫内膜异位症患者的临床资料,根据其治疗方法分为研究组与对照组,各42例。对照组患者给予诺雷德治疗,研究组患者给予宫瘤消胶囊联合诺雷德治疗,对比两组患者临床疗效、治疗前后性激素水平、血管内皮生长因子(vascular endothelial growth factor,VEGF)、血清癌抗原125(cancer antigen 125,CA 125) 和CA 199水平,并观察两组患者不良反应发生情况。结果研究组患者治疗总有效率(9524 %)高于对照组(7381 %);治疗后两组患者VEGF、CA 125、CA 199水平均较治疗前降低,且研究组患者的VEGF、CA 125、CA 199水平低于对照组;治疗后,两组患者雌二醇(estradiol,E2)水平低于治疗前,且研究组患者的E2水平低于对照组,以上各项比较,差异均有统计学意义(P<005)。两组患者的黄体生成素、卵泡刺激素水平较治疗前无明显变化(P>005)。结论宫瘤消胶囊联合诺雷德治疗子宫内膜异位症临床疗效显著,并能有效改善性激素水平,值得临床推广。
Abstract:
ObjectiveTo explore the clinical efficacy of Gongliuxiao Capsule combined with Zoladex in the treatment of endometriosis. MethodsThe clinical data of 84 patients with endometriosis treated in Shenmu City Hospital from March 2017 to February 2018 were analyzed retrospectively. According to the treatment methods, the patients were divided into the study group and the control group,each with 42 cases. The control group was given Zoladex treatment. The patients in the study group were treated with Gongliuxiao Capsule combined with Zoladex. The clinical efficacy, sex hormone levels, vascular endothelial growth factor (VEGF), serum cancer antigen 125 (CA 125) and CA 199 levels were compared between the two groups, and adverse reactions were observed in the two groups. ResultsThe total effective rate of treatment in the study group (9524 %) was higher than that in the control group (7381 %). After treatment, the levels of VEGF, CA 125, and CA 199 in both groups were lower than those before treatment, and the level of VEGF, CA 125, CA 199 in the study group was lower than that of the control group; after treatment, the levels of estradiol(E2) in the two groups were lower than those before treatment, and the E2 level of the study group was lower than that of the control group. The above differences were statistically significant (P<005). The levels of luteinizing hormone and follicle stimulating hormone in the two groups were not significantly different before treatment (P>005). ConclusionThe combination of Gongliuxiao Capsule and Zoladex in the treatment of endometriosis has a significant clinical effect and can effectively improve the level of sex hormones, which is worthy of clinical promotion.

参考文献/References:

[1]范旭虹,宗小颖.妇科千金片对子宫内膜异位症患者术后生活质量及临床疗效的影响 [J].中国生化药物杂志,2016,36(4):132-134. [2]高巍,张莉,翟丽丽,等.米非司酮联合散结镇痛胶囊治疗子宫内膜异位症患者对性激素水平的影响 [J].海南医学院学报,2016,22(22):2769-2771. [3]刘素芳,魏丽平,赵东兰,等.米非司酮联合中药对子宫内膜异位症的临床疗效及对CA 125水平的影响 [J].河北医科大学学报,2016,37(9):1026-1029. [4]李杏杏,万贵平.中药治疗子宫内膜异位症作用机制的研究进展 [J].现代中西医结合杂志,2015,24(2):210-213. [5]中华医学会妇产科学分会子宫内膜异位症协作组.子宫内膜异位症的诊断与治疗规范 [J].中华妇产科杂志,2007,42(9):645-648. [6]中华中医药学会.中医妇科常见病诊疗指南 [M].北京:中国中医药出版社,2012:120-123. [7]吴正芳,时燕萍,许家莹.中医药抗子宫内膜异位症血管生成的研究新进展 [J].河北中医,2015,37(5):790-793. [8]Yilmaz N, Ozaksit G, Keskin R, et al. The effect of formoterol on peritoneal VEGF levels in rats with endometriosis [J]. Cytokine, 2012, 58(1): 47-49. [9]Ahn JI, Yoo JY, Kim TH, et al. cAMP-response element-binding 3-like protein 1 (CREB3L1) is required for decidualization and its expression is decreased in women with endometriosis [J]. Curr Mol Med, 2016, 16(3): 276-287. [10]张丽霞,季士顺.补肾活血化瘀方联合米非司酮治疗子宫内膜异位症的效果 [J].中国妇幼保健,2014,29(19):3117-3120. [11]冷金花,戴毅.子宫内膜异位症诊治热点问题 [J].中国实用妇科与产科杂志,2014,30(1):17-20. [12]甘忠云.诺雷德联合米非司酮预防子宫内膜异位症术后复发的疗效观察 [J].浙江创伤外科,2014,19(1):29-30. [13]费春香,吴江平,吴瑛,等.宫瘤消胶囊联合散结镇痛胶囊对子宫腺肌病患者月经量、痛经的影响 [J].现代中西医结合杂志,2015,24(35):3929-3931. [14]张美楠,梁瑞宁.子宫内膜异位症血管生成相关因子及抗血管生成治疗进展 [J].江西中医药,2016,47(11):78-80. [15]张晓颖,刘芸.血清CA 125及CA 19-9测定对子宫内膜异位症的诊断价值 [J].浙江临床医学,2013,15(5):612-614.

相似文献/References:

[1]苏慧明,徐燕,李晶,等.E-钙粘附素在子宫内膜异位症盆腔腹膜病灶的表达[J].中国计划生育和妇产科,2010,(01):0.
 SU Hui-ming,XU Yan,LI Jing,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2010,(6):0.
[2]李桂兰.青春期子宫内膜异位症的诊治进展[J].中国计划生育和妇产科,2010,(03):0.
[3]韦晓娜,覃红萍.孕三烯酮配伍小剂量米非司酮治疗子宫内膜异位症64例效果观察[J].中国计划生育和妇产科,2010,(04):0.
[4]李成龙,冷金花.子宫内膜异位症与雌、孕激素受体关系的研究进展[J].中国计划生育和妇产科,2010,(04):0.
[5]关铮.深部浸润型子宫内膜异位症相关问题探讨[J].中国计划生育和妇产科,2011,(04):0.
[6]张瑞霞,刘增娟,谢伟,等.腹腔镜诊断盆腔子宫内膜异位症及对不孕症患者的疗效观察[J].中国计划生育和妇产科,2012,(02):0.
 ZHANG Rui-xia,LIU Zeng-juan,XIE Wei,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2012,(6):0.
[7]梁寿珺,范余娟,黄尹,等.血管内皮生长因子+936TC基因多态性同子宫内膜异位症遗传易感性的Meta分析[J].中国计划生育和妇产科,2012,(04):0.
 LIANG Shou-jun,FAN Yu-juan*,HUANG Yin,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2012,(6):0.
[8]范俊,栾少红,李晓林,等.口服避孕药在子宫内膜异位症治疗中的作用[J].中国计划生育和妇产科,2013,(02):0.
 FAN Jun,LUAN Shao-hong,LI Xiao-lin,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2013,(6):0.
[9]柴明涵,董白桦.左炔诺孕酮宫内缓释系统的临床应用[J].中国计划生育和妇产科,2014,(03):0.
[10]李素红,冯春蝶,付秀虹,等.Treg细胞及Foxp3在子宫内膜异位症患者的表达及临床意义[J].中国计划生育和妇产科,2014,(04):0.
 LI Su-hong,FENG Chun-die,FU Xiu-hong,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2014,(6):0.

更新日期/Last Update: 2019-06-25